Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6172429 | 0.93 | HRH3 (0.55) | HRH3TBXAS1CYP19A1PDE3BPDE3A | |
| SCHEMBL10604889 | 0.90 | HRH3 (0.60) | HRH3TBXAS1CYP19A1PDE3BPDE3A | |
| SCHEMBL6174918 | 0.82 | CYP19A1 (0.52) | TBXAS1CYP19A1PDE3BPDE3AKDM4E | |
| SCHEMBL6173341 | 0.82 | CYP19A1 (0.60) | CYP19A1PDE3BPDE3AALDH1A1MAPK1 | |
| SCHEMBL6172824 | 0.82 | CYP19A1 (0.60) | CYP19A1PDE3BPDE3AALDH1A1MAPK1 | |
| SCHEMBL6173782 | 0.81 | CYP19A1 (0.47) | HRH3TBXAS1CYP19A1PDE3BPDE3A | |
| SCHEMBL6173775 | 0.81 | CYP19A1 (0.47) | HRH3TBXAS1CYP19A1PDE3BPDE3A | |
| SCHEMBL6171877 | 0.81 | MAOB (0.56) | TBXAS1CYP19A1KDM4EALDH1A1MAPK1 | |
| SCHEMBL6176715 | 0.81 | CYP19A1 (0.62) | HRH3TBXAS1CYP19A1ALDH1A1MAOB | |
| SCHEMBL6176710 | 0.81 | CYP19A1 (0.62) | HRH3TBXAS1CYP19A1ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | claimed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | claimed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | claimed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | claimed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | claimed |
| US-4610998-A | Imidazolylethoxyindanes and use as antithrombotic agents | FERRER INTERNACIONAL, S.A. (ES) | 1986-09-09 | — | — | US | claimed |
| EP-0966446-B1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER LAMBERT CO (US) | 2005-10-19 | — | — | EP | disclosed |
| US-6528535-B2 | Anticancer agents; restenosis | WARNER-LAMBERT COMPANY | 2003-03-04 | — | — | US | disclosed |
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | BIKKER JACK (US) | 2002-01-17 | — | — | US | disclosed |
| US-6265422-B1 | ANTICANCER AGENTS; CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| US-6133303-A | VARIOUS INDENE DERIVATIVES, WITH THE EXCEPTION OF 5-(2-IMIDAZOLE-1-YL-ETHOXY)INDAN-1-ONE; TREATING CANCER AND TREATING OR PREVENTING RESTENOSIS OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0966446-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998034921-A1 | BICYCLIC INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1998-08-13 | — | — | WO | disclosed |
| EP-0184809-B1 | IMIDAZOLYLALKOXYINDANIC DERIVATIVES, A PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | FERRER INTERNACIONAL, S.A. (ES) | 1989-08-02 | — | — | EP | disclosed |
| US-4610998-A | Imidazolylethoxyindanes and use as antithrombotic agents | FERRER INTERNACIONAL, S.A. (ES) | 1986-09-09 | — | — | US | disclosed |
| EP-0184809-A1 | Imidazolylalkoxyindanic derivatives, a process for preparing them and pharmaceutical composition containing them | FERRER INTERNACIONAL, S.A. (ES) | 1986-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006936-A1 | Bicyclic inhibitors of protein farnesyl transferase | FNTA, FNTB, SREBF1 | HRH3 4628/4885TBXAS1 283/4885CYP19A1 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.